Brought to you by 
Sirna, Allergan enter multi-year deal for ophthalmic drugs
25 Jul 2006
Executive Summary
In its largest deal to date, Sirna Therapeutics (develops RNAi-based therapies) has signed a multi-year agreement with Allergan to develop Sirna027, its modified short-interfering RNA (siRNA) drug candidate for age-related macular degeneration (AMD). The companies will also discover and develop other RNAi-based therapeutics against Allergan's gene targets for ophthalmic diseases.
Deal Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sirna, Allergan enter multi-year deal for ophthalmic drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice